Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders

References

• Selby W. The natural history of ulcerative colitis. Baillieres Clin Gastroenterol 1997;11:53-64
   PubMed Web of Science ®Google Scholar
• Allison MC, Dhillon AP, Lewis WG, Pounder RE. Inflammatory Bowel Disease. London: Mosby; 1998. pp9-95
   Google Scholar
• Saniabadi AR, Hanai H, Fukunaga K, et al. Therapeutic leucocytapheresis for inflammatory bowel disease. Transfus Apher Sci 2007;37:191-200
   PubMed Web of Science ®Google Scholar
• Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997;92:5S-11S
   PubMed Web of Science ®Google Scholar
• Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29
   PubMed Web of Science ®Google Scholar
• Taffet SL, DAS KM. Sulphasalazine-adverse effects and desensitization. Dig Dis Sci 1983;28:833-42
   PubMed Web of Science ®Google Scholar
• Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000;6:48-57
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D. On behalf of an international study group, coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis. Br Med J 1989;298:82-6
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Marion JF, Salomon P, Janowitz HD. How effective is current medical therapy for severe ulcerative colitis? J Clin Gastroenterol 1995;20:280-4
   PubMed Web of Science ®Google Scholar
• Truelove SC, Jewell DP. Intensive intravenous regimens for severe attacks of ulcerative colitis. Lancet 1974;1:1067-70
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-13
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Medical therapy of ulcerative colitis. Gastroenterology 2004;126:1582-92
   PubMed Web of Science ®Google Scholar
• O’Keefe SJ. Nutrition and gastrointestinal disease. Scand J Gastroenterol 1996;220:52-9
   Google Scholar
• Kornbluth A, Marion JF, Salomon P, Janowitz HD. How effective is current medical therapy for severe ulcerative colitis? J Clin Gastroenterol 1995;20:280-4
   PubMed Web of Science ®Google Scholar
• Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998;10:411-13
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Can Cyclosporine go it alone in severe ulcerative colitis. Curr Gastroenterol Rep 2001;3:455-6
   PubMedGoogle Scholar
• Serkova NJ, Christians U, Benet LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv 2004;4:97-107
   PubMed Web of Science ®Google Scholar
• Tanaka T, Okanobu H, Kuga Y, et al. Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol 2010;34:687-95
   PubMedGoogle Scholar
• Saniabadi AR, Hanai H. Therapeutic apheresis from the early civilizations to the twenty-first century. Gastroenterol Clin Biol 2010;34:645-8
   PubMedGoogle Scholar
• Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000;51:289-98
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
   PubMed Web of Science ®Google Scholar
• van Dullemen HM, van Deventer SJ, Hommes DW. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35
   PubMed Web of Science ®Google Scholar
• Brown SL, Greene MH, Gershon SK. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8
   PubMed Web of Science ®Google Scholar
• Atzeni A, Ardizzone S, Sarzi-Puttini P. Autoantibody profile during short-term infliximab treatment for Crohn’s disease: a prospective cohort study. Aliment Pharmacol Ther 2005;22:453-61
   PubMed Web of Science ®Google Scholar
• McCarthy DA, Rampton DS, Liu Y-C. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 1991;86:489-93
   PubMed Web of Science ®Google Scholar
• Heimann TM, Aufses AHJr. The role of peripheral lymphocytes in the prediction of recurrence in Crohn’s disease. Surg Gynecol Obstet 1985;160:295-8
   PubMedGoogle Scholar
• Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective neutrophil and monocyte adsorptive apheresis as a first line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004;49:565-71
   PubMed Web of Science ®Google Scholar
• Aoki H, Nakamura K, Suzuki Y. Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8 and the expression of toll like receptor 2 on granulocytes. Dig Dis Sci 2007;52:1427-33
   PubMed Web of Science ®Google Scholar
• Tanaka T, Okanobu H, Murakami E. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naive patients. Dig Liver Dis 2008;40:731-6
   PubMedGoogle Scholar
• Tibble JA, Sigthorsson G, Bridger D, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22
   PubMed Web of Science ®Google Scholar
• Schreiber S, Nikolaus S, Hampe J. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn’s disease. Lancet 1999;353:459-61
   PubMed Web of Science ®Google Scholar
• Brannigan AE, O’Connell PR, Hurley H. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 2000;13:361-6
   PubMed Web of Science ®Google Scholar
• Lee A, Whyte M, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol 1993;54:283-8
   PubMed Web of Science ®Google Scholar
• Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996;156:4422-8
   PubMed Web of Science ®Google Scholar
• Belge KU, Ziegler-Heitbrock HW. The proinflammatory CD14+CD16+ monocytes are a major source of TNF. J Immunol 2002;168:3536-42
   PubMed Web of Science ®Google Scholar
• Hanai H, Iida T, Takeuchi K. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol 2008;103:1210-16
   PubMed Web of Science ®Google Scholar
• Cohen RD. Treating ulcerative colitis without medications – “Look Mom, No Drugs!”. Gastroenterology 2005;128:235-6
   PubMedGoogle Scholar
• Sands BE, Sandborn WJ, Feagan B. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008;135:400-9
   PubMed Web of Science ®Google Scholar
• Powrie F, Read S, Mottet C, et al. Control of immune pathology by regulatory T cells. Novartis Found Symp 2003;252:92-8
   PubMedGoogle Scholar
• Maul J, Loddenkemper C, Mundt P, Duchmann R. Peripheral and intestinal regulatory CD4+CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005;128:1868-78
   PubMed Web of Science ®Google Scholar
• Uhlig HH, Powrie F. The role of mucosal T lymphocytes in regulating intestinal inflammation. Immunopathol 2005;27:167-80
   PubMed Web of Science ®Google Scholar
• Liu H, Hu B, Xu D, Liew FY. CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4. J Immunol 2003;171:5012-17
   PubMed Web of Science ®Google Scholar
• Huber S, Schramm C, Lehr HA, Blessing M. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 2004;173:6526-31
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Fukunaga K, Fukuda Y, Matsumoto T. Demonstration of Low-Regulatory CD25(High+)CD4(+) and high-pro-inflammatory CD28(-)CD4(+) T-cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci 2007;52:2725-31
   PubMed Web of Science ®Google Scholar
• Saniabadi AR, Hanai H, Takeuchi K, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003;7:48-59
   PubMed Web of Science ®Google Scholar
• Saniabadi AR, Hanai H, Sawada K, et al. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher 2005;20:171-84
   PubMed Web of Science ®Google Scholar
• D’Arrigo C, Candal-Couto JJ, Greer M, et al. Human neutrophil Fc receptor-mediated adhesion under flow: a hallow fiber model of intravascular arrest. Clin Exp Immunol 1993;100:173-9
   Web of Science ®Google Scholar
• Hiraishi K, Takeda Y, Saniabadi A, et al. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 2003;7:334-40
   PubMed Web of Science ®Google Scholar
• Hanai H, Takeda Y, Saniabadi AR, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011;163:50-8
   PubMed Web of Science ®Google Scholar
• Hanai H, Watanabe F, Takeuchi K, Bjarnason I. Leukcocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin Gastroenterol Hepatol 2003;1:28-35
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Yoshimura N, Saito Y, Saniabadi A. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006;51:2031-8
   PubMed Web of Science ®Google Scholar
• Habermalz B, Sauerland S. Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis. Dig Dis Sci 2010;55:1421-8
   PubMed Web of Science ®Google Scholar
• Yoshino T, Nakase H, Minami N, et al. Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta-analysis. Dig Liver Dis 2014;46:219-26
   PubMedGoogle Scholar